CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company developing chimeric engulfment receptor T-cell therapies targeting cancer. The company entered the public markets through its business combination with Phoenix Biotech Acquisition Corp, a blank-check vehicle that completed its IPO in 2021 and was sponsored by Phoenix Biotech Sponsor, LLC. Following the close of its de-SPAC transaction in early 2023, CERO filed an 8-K with the Securities and Exchange Commission on January 5, 2024, reflecting its ongoing reporting obligations as a public company operating in the oncology biotechnology sector. For comprehensive filings, deal history, and real-time SPAC analytics on CERO and the broader SPAC market, sign up for full data access at SpacDesk.